Hisao Uejima

803 total citations
22 papers, 549 citations indexed

About

Hisao Uejima is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Hisao Uejima has authored 22 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 15 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Hisao Uejima's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Hisao Uejima is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (9 papers) and Cancer therapeutics and mechanisms (6 papers). Hisao Uejima collaborates with scholars based in Japan. Hisao Uejima's co-authors include Kazuhiko Nakagawa, Masahiro Fukuoka, Takayasu Kurata, Miyako Satouchi, Koji Takeda, Nobuyuki Yamamoto, Toyoaki Hida, Kenji Tamura, Hiroyasu Kaneda and Yasumasa Nishimura and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Thoracic Oncology.

In The Last Decade

Hisao Uejima

21 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hisao Uejima Japan 11 374 371 127 44 35 22 549
H. Bülzebruck Germany 10 263 0.7× 200 0.5× 67 0.5× 46 1.0× 18 0.5× 23 400
S. Seeber Germany 12 162 0.4× 262 0.7× 158 1.2× 44 1.0× 13 0.4× 55 445
Y. Nakanishi Japan 6 440 1.2× 233 0.6× 109 0.9× 86 2.0× 19 0.5× 7 613
Larry Schlabach United States 8 151 0.4× 185 0.5× 101 0.8× 27 0.6× 28 0.8× 10 300
Matteo Perrino Italy 15 372 1.0× 166 0.4× 137 1.1× 60 1.4× 37 1.1× 48 670
Gary P. Gamble United States 7 470 1.3× 260 0.7× 177 1.4× 94 2.1× 48 1.4× 9 636
Daniel P. Petro United States 11 194 0.5× 243 0.7× 188 1.5× 31 0.7× 54 1.5× 21 428
Raffaele Piscitelli Italy 8 149 0.4× 87 0.2× 146 1.1× 20 0.5× 26 0.7× 18 336
S Spaventi Croatia 8 133 0.4× 288 0.8× 144 1.1× 86 2.0× 41 1.2× 24 426
Elaine Shum United States 13 348 0.9× 388 1.0× 176 1.4× 62 1.4× 18 0.5× 52 586

Countries citing papers authored by Hisao Uejima

Since Specialization
Citations

This map shows the geographic impact of Hisao Uejima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hisao Uejima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hisao Uejima more than expected).

Fields of papers citing papers by Hisao Uejima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hisao Uejima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hisao Uejima. The network helps show where Hisao Uejima may publish in the future.

Co-authorship network of co-authors of Hisao Uejima

This figure shows the co-authorship network connecting the top 25 collaborators of Hisao Uejima. A scholar is included among the top collaborators of Hisao Uejima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hisao Uejima. Hisao Uejima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yamamoto, Nobuyuki, Kazuhiko Nakagawa, Yasumasa Nishimura, et al.. (2010). Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Non–Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. Journal of Clinical Oncology. 28(23). 3739–3745. 220 indexed citations
2.
Takezawa, Ken, Isamu Okamoto, Junya Fukuoka, et al.. (2008). Large Cell Neuroendocrine Carcinoma of the Mediastinum with α-Fetoprotein Production. Journal of Thoracic Oncology. 3(2). 187–189. 12 indexed citations
3.
Nakagawa, Ken, Haruka Minami, Akihira Mukaiyama, et al.. (2008). Phase I Dose-escalation and Pharmacokinetic Trial of Lapatinib (GW572016), a Selective Oral Dual Inhibitor of ErbB-1 and -2 Tyrosine Kinases, in Japanese Patients with Solid Tumors. Japanese Journal of Clinical Oncology. 39(2). 116–123. 18 indexed citations
4.
Yoshida, Keisuke, Hisao Uejima, Miyako Satouchi, et al.. (2007). 切除不能な第III期非小細胞肺癌(NSCLC)に対するマイトシン/ビンデシン/シスプラチン(MVP)対毎週のイリノテカン/カルボプラチン(PC)同時併用胸部放射線療法(TRT)の無作為第III相試験:WJTOG0105. Journal of Thoracic Oncology. 2(8). 365–366. 6 indexed citations
5.
6.
Nishimura, Takashi, Nobuyuki Katakami, Masashi Kobayashi, et al.. (2007). P3-121: Phase II study of gefitinib as a first–line therapy in elderly patients with lung adenocarcinoma (WJTOG 0402–DI). Journal of Thoracic Oncology. 2(8). S730–S731. 2 indexed citations
7.
Kaneda, Hiroyasu, Takayasu Kurata, Kenji Tamura, et al.. (2006). A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.. PubMed. 26(3B). 2479–85. 8 indexed citations
8.
Asai, Gyo, Nobuyuki Yamamoto, Takayasu Kurata, et al.. (2006). Phase I and Pharmacokinetic Study of Combination Chemotherapy Using Irinotecan and Paclitaxel in Patients with Lung Cancer. Journal of Thoracic Oncology. 1(3). 226–230. 4 indexed citations
9.
Yamamoto, Nobuyuki, Kazuhiko Nakagawa, Hisao Uejima, et al.. (2006). Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer. Cancer. 107(3). 599–605. 22 indexed citations
10.
Sakamaki, Yasushi, et al.. (2006). Pulmonary lymphoma of mucosa-associated lymphoid tissue type followed as a long-standing indeterminate lesion in immunoglobulin M-type paraproteinemia. General Thoracic and Cardiovascular Surgery. 54(7). 293–296. 3 indexed citations
11.
Kurata, Takayasu, Hiroyasu Kaneda, Kenji Tamura, et al.. (2005). A combination phase I study of amrubicin and irinotecan (CPT-11) in patients with lung cancer. Journal of Clinical Oncology. 23(16_suppl). 7332–7332.
12.
Minami, Hironobu, Katsuhiro Nakagawa, Kenji Kawada, et al.. (2004). A phase I study of GW572016 in patients with solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3048–3048. 16 indexed citations
13.
Kaneda, Hiroyasu, Kenji Tamura, Takayasu Kurata, et al.. (2004). Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer. Lung Cancer. 46(2). 247–254. 55 indexed citations
14.
15.
Tsurutani, Junji, Takashi Nitta, Tomonori Hirashima, et al.. (2002). Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan. Lung Cancer. 35(3). 299–304. 39 indexed citations
16.
Takeda, Koji, et al.. (2002). Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer. Lung Cancer. 38(3). 303–308. 10 indexed citations
17.
Tsurutani, Junji, Takefumi Komiya, Hisao Uejima, et al.. (2002). Mutational analysis of the β-tubulin gene in lung cancer. Lung Cancer. 35(1). 11–16. 43 indexed citations
18.
Tohda, Yuji, et al.. (1996). Assessment of serum CYFRA 21-1 in lung cancer. Cancer. 77(7). 1274–1277. 33 indexed citations
19.
Tohda, Yuji, Takashi Iwanaga, Hisao Uejima, Yukio Nagasaka, & Shigenori Nakajima. (1996). Effects of Cytokines on Oxygen Radical Production by Peripheral Blood Monocytes and Alveolar Macrophages in Patients with Lung Cancer. Tumori Journal. 82(4). 382–385. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by H. Bülzebruck Breakdown of academic impact, for papers by S. Seeber Breakdown of academic impact, for papers by Y. Nakanishi Breakdown of academic impact, for papers by Larry Schlabach Breakdown of academic impact, for papers by Matteo Perrino Breakdown of academic impact, for papers by Gary P. Gamble Breakdown of academic impact, for papers by Daniel P. Petro Breakdown of academic impact, for papers by Raffaele Piscitelli Breakdown of academic impact, for papers by S Spaventi Breakdown of academic impact, for papers by Elaine Shum
Rankless by CCL
2026